Literature DB >> 7497535

Inflammatory myopathies.

C V Oddis1, T A Medsger.   

Abstract

New information regarding myositis specific autoantibodies, histopathologic analysis of muscle biopsy specimens, and immunogenetic features of the different serologic subsets of disease has greatly increased our understanding of the pathogenesis of the inflammatory myopathies. The clinical descriptions of inclusion body myositis and 'amyopathic dermatomyositis' (Euwer and Sontheimer, 1993) are examples of our expanded descriptive capabilities in the evaluation of patients with myopathy. Finally, newer techniques such as cytokine analysis and magnetic resonance imaging may help in the ongoing assessment of disease activity in patients with myositis. The combination of these recently described clinical and laboratory parameters are enough to force a reconsideration of the previously described classification and diagnostic criteria in the inflammatory myopathies.

Entities:  

Mesh:

Year:  1995        PMID: 7497535     DOI: 10.1016/s0950-3579(05)80255-9

Source DB:  PubMed          Journal:  Baillieres Clin Rheumatol        ISSN: 0950-3579


  4 in total

Review 1.  Diagnosis and classification of idiopathic inflammatory myopathies.

Authors:  I E Lundberg; F W Miller; A Tjärnlund; M Bottai
Journal:  J Intern Med       Date:  2016-07       Impact factor: 8.989

Review 2.  Selected aspects of the current management of myositis.

Authors:  James Lilleker; Sean Murphy; Robert Cooper
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-06-19       Impact factor: 5.346

3.  Profile of specific and associated autoantibodies in patients with idiopathic inflammatory myopathies in a Colombian population.

Authors:  Andrés Hormaza-Jaramillo; Vanessa Bedoya-Joaqui; Germán Puerta-Sarmiento; Mario Bautista; Lady J Rios-Serna; Tatiana Delgado-Mora; Ivana Nieto-Aristizábal; Ingrid Ruiz-Ordoñez
Journal:  Front Med (Lausanne)       Date:  2022-08-15

Review 4.  New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter.

Authors:  Valérie Leclair; Ingrid E Lundberg
Journal:  Curr Rheumatol Rep       Date:  2018-03-17       Impact factor: 4.592

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.